# Renda Kangjian

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/renda-kangjian

- Industry: Biotechnology
- Headquarters: Xianyang, China
- Latest round: Angel (Sep 1, 2023)
- Investors on record: 1

## About

Founded in 2022 and based in Xianyang, China, Renda Kangjian Renda operates as a biopharmaceutical company that focuses on the research and development of anti-Alzheimer drugs and related products. It was founded by the team of Wenxia Han from Xi’an Medical University. The company acquired more than 10 invention patents in the field of Huperzine A API. Renda Kangjian closed an angel funding in September 2023. The company was approved for more than 700 square meters of factory land in early 2024. In June 2024, Renda Kangjian raised a strategic investment for CNY 3 million.

Renda Kangjian mainly engages in the research and development of anti-Alzheimer drugs. Its main product is Huperzine A APIs. Its synthesized Huperzine A are synthesized based on self-developed biosynthesis technologies, which also preserve the composition and activity. Products can be used in the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

The company generates revenue by providing anti-Alzheimer drugs and related products.

The company will use the strategic investment for technology development and product promotion.

## Funding rounds

- Angel, Sep 1, 2023 — Xixian New Area Financial Holding Capital

## Investors

- Xixian New Area Financial Holding Capital (https://capitalatlas.ai/funds/xixian-new-area-financial-holding-capital) — Angel